Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …

Equipping cancer-fighting immune cells with chimeric antigen receptor (CAR) has gained
immense attention for cancer treatment. CAR-engineered T cells (CAR T cells) are the first …

In recent years, immunotherapy for cancer has become mainstream with several products
now authorized for therapeutic use in the clinic and are becoming the standard of care for …

Genome engineered natural killer (NK) cell therapies are emerging as a promising cancer
immunotherapy platform with potential advantages and remaining uncertainties. Feeder …

Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …

High-Grade Gliomas (HGG) are among the deadliest malignant tumors of central nervous
system (CNS) in pediatrics. Despite aggressive multimodal treatment-including surgical …

Natural killer cells are a promising platform for cancer immunotherapy. Natural killer cells
have high intrinsic killing capability, and the insertion of a chimeric antigen receptor can …

Background Natural killer (NK) cell genome editing promises to enhance the innate and
alloreactive anti-tumor potential of NK cell adoptive transfer. DNA transposons are versatile …

Augmenting cells with novel, genetically encoded functions will support therapies that
expand beyond natural capacity for immune surveillance and tissue regeneration. However …

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is a novel immunotherapy
targeting cancer cells via the generation of chimeric antigen receptors on NK cells which …